F-10POS: Oncolytics Biotech Withdraws Unsold Securities from Registration

Sentiment:

Securities Withdrawal


Oncolytics Biotech files post-effective amendment to deregister unsold securities from multiple prior F-10 registration statements.

Summary

  • Oncolytics Biotech Inc. has filed a post-effective amendment to several of its Form F-10 registration statements.
  • The primary purpose of this filing is to withdraw the unsold portion of securities that were previously registered.
  • This action pertains to multiple registration statements filed between 2007 and 2024, covering various types of securities including units, common shares, subscription receipts, warrants, and debt securities.
  • The amendment specifically revises the designated effectiveness date and time for the registration statements to April 8, 2026, at 4:30 p.m. Eastern time, solely for the purpose of this withdrawal.
  • No other changes have been made to the previously filed registration statements.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing, as it indicates that previously registered securities were not sold, suggesting a lack of demand or a change in capital needs.

Future Outlook

This filing does not contain forward-looking statements or guidance; it is solely for the administrative purpose of withdrawing previously registered but unsold securities.

Industry Context

StockSavvy.ai notes that this filing is a procedural administrative action related to past capital-raising activities rather than a current operational or financial update. Companies often withdraw unused shelf registrations when they are no longer needed.

Stakeholder Impact

  • Shareholders: This filing does not directly impact current shareholders as it pertains to securities that were not sold. It may indirectly suggest past difficulties in raising capital through these specific offerings.

Next Steps

  • The withdrawal of unsold securities from the registration statements will become effective on April 8, 2026.

Key Dates

DateDescription
2007-02-02Initial filing date for Registration Statement No. 333-140460.
2007-02-08Initial filing date for Registration Statement No. 333-140529.
2008-06-06Initial filing date for Registration Statement No. 333-151513.
2010-06-02Initial filing date for Registration Statement No. 333-167250.
2012-06-21Initial filing date for Registration Statement No. 333-182260.
2014-07-25Initial filing date for Registration Statement No. 333-197633.
2018-04-25Initial filing date for Registration Statement No. 333-224432.
2020-06-08Initial filing date for Registration Statement No. 333-239025.
2022-06-10Initial filing date for Registration Statement No. 333-265510.
2024-07-25Initial filing date for Registration Statement No. 333-281009.
2026-04-06Date of filing of Post-Effective Amendment No. 2.
2026-04-08Designated effectiveness date and time for the post-effective amendment (4:30 p.m. Eastern time).

Keywords

Oncolytics Biotech, SEC Filing, Form F-10, Registration Statement, Securities Withdrawal, Deregistration, Post-Effective Amendment

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.